Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... the risk of cancer returning,after surgery for ... April 12, 2007 /PRNewswire/ -- Investigators,will begin ... placebo in a major North American clinical ... Kit-positive,gastrointestinal stromal tumors treated with Gleevec following,surgery ...
... and NUTLEY, N.J., April 12, 2007,/PRNewswire-FirstCall/ -- ... trial program ever undertaken in the renal,anemia ... the,investigational anemia therapy MIRCERA(TM) for the treatment ... (CKD) in,patients on dialysis and not on ...
Cached Medicine Technology:Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 2Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 3Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 4Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 5Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 6Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 7Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 2Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 3Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 4
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently ... molecule in metastatic breast cancer reduces both the growth ... BRI scientists have found in models of the disease ... - 80 percent and can keep the tumor from ... five-year grant comes from the National Cancer Institute of ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... new studies show higher joint replacement complication rates, longer ... The prevalence of obesity is rising at ... with this life-altering condition may be putting their long-term ... at the 2009 Annual Meeting of the American ...
... Orthopaedic surgeon John J. Callaghan, MD was elected to ... Orthopaedic Surgeons ( http://www.aaos.org/ )(AAOS) at the organization,s 2009 ... Academy as First Vice-President.Having to wear a cast as a ... go into the field of orthopaedic surgery. "Breaking my ...
... that boys and girls can return to high-level sports ... high school athletes receiving anterior cruciate ligament ( ACL ... return to their sport at the same level, and ... rate. A new study presented today at the 2009 ...
... for psychiatric services following an emergency room visit are ... call for help, compared to about 20 percent of ... percent of all calls to mental health clinics in ... two weeks, according to a new University of Pennsylvania ...
... February 2009 Molecular Oncology (MOLONC) ... of the Federation of European Biochemical Societies (FEBS), ... for inclusion in the Science Citation Index Expanded ... , MOLONC (published 6 times a year from ...
... 8x BD writer drive, Vinpower Digital is able to offer the ... , ... Los Angeles, CA (PRWEB) February 25, 2009 ... Disc duplicator lines offering true 8X BD-R duplication speed. Using ...
Cached Medicine News:Health News:Obesity: A Musculoskeletal Nightmare 2Health News:Obesity: A Musculoskeletal Nightmare 3Health News:Obesity: A Musculoskeletal Nightmare 4Health News:John J. Callaghan, MD Elected Academy First Vice President 2Health News:John J. Callaghan, MD Elected Academy First Vice President 3Health News:Getting on the Ball, Post-ACL Surgery 2Health News:Getting on the Ball, Post-ACL Surgery 3Health News:For psychiatric services, wait for the beep 2Health News:For psychiatric services, wait for the beep 3Health News:Molecular Oncology accepted into Thomson Reuters index 2Health News:Vinpower Digital Increases Blu-ray Disc Duplication Speed to 8X for Both Their Manual Tower and Autoloader Series Duplicators 2Health News:Vinpower Digital Increases Blu-ray Disc Duplication Speed to 8X for Both Their Manual Tower and Autoloader Series Duplicators 3
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Assay for Determination of Initial Thrombin Formation...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit PiCT LMWH Calibrators...
Medicine Products: